FDA grants BeOne's Beqalzi accelerated approval in mantle cell lymphoma after a BTK inhibitor
Sonrotoclax produced responses in 52% of 103 previously treated patients in a single-arm trial, with a median duration of 15.8 months.
Sonrotoclax produced responses in 52% of 103 previously treated patients in a single-arm trial, with a median duration of 15.8 months.